APA (7th ed.) Citation

KW, P., JM, L., SH, K., HS, A., HM, Y., HY, L., . . . HS, K. (2013). Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice: Patient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries. Journal of the American College of Cardiology (JACC), 61(5), 536. https://doi.org/10.1016/j.jacc.2012.11.015

Chicago Style (17th ed.) Citation

KW, Park, et al. "Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice: Patient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries." Journal of the American College of Cardiology (JACC) 61, no. 5 (2013): 536. https://doi.org/10.1016/j.jacc.2012.11.015.

MLA (9th ed.) Citation

KW, Park, et al. "Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice: Patient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries." Journal of the American College of Cardiology (JACC), vol. 61, no. 5, 2013, p. 536, https://doi.org/10.1016/j.jacc.2012.11.015.